James Collins
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About James Collins
Earlier roles on record: Board Member at Fulcrum Therapeutics, Inc. (FULC) until November 12, 2024. Fulcrum Therapeutics, Inc. reported in an 8-K filed November 12, 2024 that James Collins resigned as Class II director, effective November 12, 2024.
“On November 12, 2024, James J. Collins, a Class II director, notified the board of directors, or the Board, of Fulcrum Therapeutics, Inc., or Fulcrum, of his decision to resign as a member of the Board and all committees thereof, with immediate effect.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
2024-06-17–2024-11-12
Company network
Recorded roles and call appearances connecting this person to public companies.
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.